Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian Clinical Labs Ltd ( (AU:ACL) ) has issued an update.
Australian Clinical Labs has disclosed that institutional investor United Super Pty Ltd has ceased to be a substantial holder in the company as of 13 April 2026. The change was formalised in a statutory notice lodged under the Corporations Act, indicating that United Super’s voting interest has fallen below the substantial holding threshold and that no new associate relationships have arisen in connection with this change.
The cessation of United Super as a substantial shareholder may alter the company’s investor base and could modestly impact perceptions of institutional support, although no details were provided on the precise size or structure of the remaining stake. The filing primarily serves as a regulatory update for the market and stakeholders on shifts in major shareholdings in Australian Clinical Labs.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited operates in the pathology and medical diagnostics industry, providing laboratory testing services to healthcare providers, hospitals and patients. The company focuses on clinical pathology services across Australia, supporting diagnosis and treatment decisions in the broader healthcare system.
Average Trading Volume: 838,781
Technical Sentiment Signal: Sell
Current Market Cap: A$380.1M
Learn more about ACL stock on TipRanks’ Stock Analysis page.